Company: TXG
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001770787-25-000051
Chunk: 11

Company: 10x Genomics, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 1
Chunk 11
---
 economic conditions. The Company recognizes an allowance for credit losses, up to the amount of the unrealized loss when appropriate, and writes down the amortized cost basis of the investment if it is more likely than not that the Company will be required or will intend to sell the investment before recovery of its amortized cost basis. Allowances for credit losses and write-downs are recognized in “Other expense, net,” and unrealized losses not related to credit losses are recognized in “Accumulated other comprehensive income (loss).” There are no allowances for credit losses for the periods presented.InventoryInventory was comprised of the following (in thousands):June 30,2025December 31,2024Purchased materials$20,544 $38,930 Work in progress29,626 27,441 Finished goods18,798 16,736 Inventory$68,968 $83,107 Property and Equipment, NetProperty and equipment, net consisted of the following (in thousands): 

10

Table of Contents10x Genomics, Inc.Notes to Unaudited Condensed Consolidated Financial Statements

June 30,2025December 31,2024Land$36,765 $36,765 Building147,493 147,094 Laboratory equipment and machinery 76,899 72,498 Computer equipment and software15,121 14,953 Furniture and fixtures9,854 9,586 Leasehold improvements90,631 89,567 Construction in progress2,737 5,152 Total property and equipment379,500 375,615 Less: accumulated depreciation and amortization (139,790)(122,967)Property and equipment, net$239,710 $252,648 During the six months ended June 30, 2025, the Company recorded impairment charges of $0.1 million related to equipment, which was triggered by a decision to discontinue an engineering project. During the three months ended June 30, 2025, the Company had no impairment charges.During the three and six months ended June 30, 2024, the Company recorded impairment charges of $2.1 million related to computer equipment and software of which $0.3 million, $0.7 million and $1.1 million was classified in cost of revenue, research and development, and selling, general and administrative expenses, respectively, in the condensed consolidated statement of operations. The impairment charge